Another day…another approval.
9 more clinical sites to be rapidly activated in a country with a growing incidence of IIH cases.
Management ticking boxes while shareholders continue to have a golden opportunity to invest near all time lows in a company that has continually de-risked the fundamentals thesis.
Looking forward to the quarterly.
Another day…another approval.9 more clinical sites to be rapidly...
Add to My Watchlist
What is My Watchlist?
